Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 7/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.51 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.42 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 2/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 2/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | GAK | O14976 | 1/20 | 0.38 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.38 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.38 |
| ▸ | STK16 | O75716 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2051073 | 0.80 | MAP3K14 (0.57) | MAP3K14AURKAAURKBINCENPTPX2 | |
| SCHEMBL30147790 | 0.78 | AURKA (0.56) | MAP3K14AURKAAURKBINCENPTPX2 | |
| SCHEMBL3430462 | 0.78 | AURKA (0.56) | MAP3K14AURKAAURKBINCENPTPX2 | |
| SCHEMBL3850416 | 0.77 | SMN1; SMN2 (0.49) | ACVR1AKT1ALKPIM1PIM3 | |
| SCHEMBL30440259 | 0.76 | PIK3CA (0.62) | AURKAAURKBPIK3CAACVR1NCF1 | |
| SCHEMBL12277881 | 0.76 | PIK3CA (0.62) | AURKAAURKBPIK3CAACVR1NCF1 | |
| SCHEMBL731933 | 0.76 | PIK3CA (0.62) | PIK3CANCF1AKT1SLC22A12PIM1 | |
| SCHEMBL732236 | 0.76 | PIK3CA (0.43) | PIK3CAACVR1NCF1AKT1SLC22A12 | |
| SCHEMBL17833787 | 0.74 | PIK3CA (0.48) | AURKAAURKBPIK3CAACVR1NCF1 | |
| SCHEMBL27729491 | 0.74 | HTR1A (0.52) | PIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2596793-B1 | Quinoline derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2015-07-08 | — | — | EP | disclosed |
| US-20140296224-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2014-10-02 | — | — | US | disclosed |
| US-8785433-B2 | Quinoline derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-07-22 | — | — | US | disclosed |
| US-20140100234-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-04-10 | — | — | US | disclosed |
| US-8633187-B2 | Quinoline derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-01-21 | — | — | US | disclosed |
| CN-101754759-B | Quinoline derivatives as PI3 kinase inhibitors | SMITHKLINE BEECHAM CORP | 2013-10-09 | — | — | CN | disclosed |
| EP-2596793-A1 | Quinoline derivatives as PI3 kinase inhibitors | Glaxosmithkline LLC (US) | 2013-05-29 | — | — | EP | disclosed |
| US-8404837-B2 | Quinoline derivatives as P13 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120165321-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2012-06-28 | — | — | US | disclosed |
| US-8138347-B2 | Quinoline derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100168100-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-07-01 | — | — | US | disclosed |
| CN-101754759-A | Quinoline derivatives as PI3 kinase inhibitors | SMITHKLINE BEECHAM CORP | 2010-06-23 | — | — | CN | disclosed |
| US-20100152112-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2010-06-17 | — | — | US | disclosed |
| EP-2192902-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-06-09 | — | — | EP | disclosed |
| US-20080300239-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| WO-2008144464-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008144463-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152112-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | JAK3, PI4KA, PIP4K2A | MAP3K14 76/4885AURKA 376/4885AURKB 421/4885 |
| US-20140100234-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PIK3CG, PIK3CB | MAP3K14 192/4885AURKA 458/4885AURKB 437/4885 |
| US-20100168100-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | JAK3, PI4KA, PIP4K2A | MAP3K14 76/4885AURKA 376/4885AURKB 421/4885 |
| US-20120165321-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PIK3CG, PIK3CB | MAP3K14 192/4885AURKA 458/4885AURKB 437/4885 |
| US-20140296224-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PIK3CG, PIK3CB | MAP3K14 192/4885AURKA 458/4885AURKB 437/4885 |
| US-20080300239-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PIK3CG, PIK3CB | MAP3K14 192/4885AURKA 458/4885AURKB 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.